This webinar will focus on teratogens and pharmacovigilance as part of the prevention of congenital anomalies. Representatives from World Health Organization will present the Pharmacovigilance Pregnancy Exposure Registry, their initiative on how to improve monitoring drug safety among pregnant women on antiretrovirals, and the future initiatives for pharmacovigilance in pregnant women. Lessons learned in Botswana from the initial dolutegravir- neural tube defect findings, and communication of unexpected news. Efforts towards an African platform for congenital anomalies in Burkina Faso initially focusing on Zika and maternal infections will be presented.

Dr Marie-Eve Raguenaud, Dr Francoise Renaud, Dr Noha Iessa : The WHO Pregnancy exposure registry for monitoring medication safety and related actions for pharmacovigilance in pregnancy.

Dr Rebecca Zash and Ms Modiego Diseko: Communicating the unexpected safety signal from the Tsepamo Study: the good, the bad and the ugly.

Dr Ali Sié, Dr Eric Nébié, Prof. Bassirou Bonfoh, Prof. Thomas Jaenisch: Towards an African platform for congenital abnormalities and birth defects, with a focus on Zika and maternal infections.